Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

Joseph, Joanne; Rabbolini, David; Enjeti, Anoop K; Favaloro, Emmanuel; Kopp, Marie‐Christine; McRae, Simon; Pasalic, Leonardo; Tan, Chee Wee; Ward, Christopher M; Chong, Beng H

doi:10.5694/mja2.50213

ARTICLE
AUTHORS
REFERENCES
RESPONSES

Topics

Pharmaceutical preparations

Hematologic diseases

General medicine

Abstract

Introduction: Heparin‐induced thrombocytopenia (HIT) is a prothrombotic disorder that occurs following the administration of heparin and is caused by antibodies to platelet factor 4 and heparin. Diagnosis of HIT is essential to guide treatment strategies using non‐heparin anticoagulants and to avoid unwanted and potential fatal thromboembolic complications. This consensus statement, formulated by members of the Thrombosis and Haemostasis Society of Australia and New Zealand, provides an update on HIT pathogenesis and guidance on the diagnosis and management of patients with suspected or confirmed HIT.

Main recommendations:

A 4Ts score is recommended for all patients with suspected HIT prior to laboratory testing.
Further laboratory testing with a screening immunoassay or confirmatory functional assay is not recommended in individuals with a low 4Ts score. However, if there are missing or unreliable clinical data, then laboratory testing should be performed.
A positive functional assay result confirms the diagnosis of HIT and should be performed to confirm a positive immunoassay result.
Heparin exposure must be ceased in patients with suspected or confirmed HIT and initial treatment with a non‐heparin alternative instituted.
Non‐heparin anticoagulants (danaparoid, argatroban, fondaparinux and bivalirudin) used to treat HIT should be given in therapeutic rather than prophylactic doses.
Direct oral anticoagulants may be used in place of warfarin after patients with HIT have responded to alternative parenteral anticoagulants with platelet count recovery.

Changes in management as a result of this statement:

These are the first Australasian recommendations for diagnosis and management of HIT, with a focus on locally available diagnostic assays and therapeutic options.
The importance of examining both clinical and laboratory data in considering a diagnosis of HIT cannot be overstated.

Joanne Joseph¹^,²
David Rabbolini³^,⁴
Anoop K Enjeti⁵
Emmanuel Favaloro⁶^,⁷
Marie‐Christine Kopp⁴
Simon McRae⁸
Leonardo Pasalic⁶^,⁷
Chee Wee Tan⁸
Christopher M Ward³^,⁴
Beng H Chong⁹

1 St Vincent's Hospital, Sydney, NSW
2 St Vincent's Clinical School, University of New South Wales, Sydney, NSW
3 Royal North Shore Hospital, Sydney, NSW
4 Northern Blood Research Centre, Kolling Institute of Medical Research, Sydney, NSW
5 Calvary Mater Hospital, Sydney, NSW
6 Institute of Clinical Pathology and Medical Research, Sydney, NSW
7 Westmead Hospital, Sydney, NSW
8 Royal Adelaide Hospital, Adelaide, SA
9 St George Hospital, Sydney, NSW

Correspondence: Joanne.Joseph@svha.org.au

Competing interests:

Anoop Enjeti has received speaker fees from Bayer and Sanofi Aventis outside the submitted work. Simon McRae has received research funding from CSL and Roche outside the submitted work. Chee Wee Tan has received non‐financial support from Bayer Health and speaker fees from Pfizer outside the submitted work. Christopher Ward has received personal fees and non‐financial support from Aspen, personal fees from Instrumentation Laboratory (Werfen) and personal fees from Sanofi during the preparation of this consensus statement.

Responses are now closed for this article.

Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

Topics

Abstract

Author

Comment

Do you have any competing interests to declare? *